Comparison of Standard Versus Low Dose Advagraf® With or Without Angiotensin-converting Enzyme Inhibitor (ACEi)/Angiotensin Receptor Blocker (ARB) on Histology and Function of Renal Allografts
A Comparison of Effects of Standard Dose vs. Low Dose Advagraf® With IL-2 Receptor Antibody Induction, MMF and Steroids, With or Without ACEi/ARB - Based Antihypertensive Therapy on Renal Allograft Histology, Function, and Immune Response
Sponsor: Astellas Pharma Canada, Inc.
This PHASE3 trial investigates Kidney Transplantation and is currently completed. Astellas Pharma Canada, Inc. leads this study, which shows 12 recorded versions since 2009 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
12 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Dec 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Nov 2024 — Dec 2024 [monthly]
Completed PHASE3
-
Sep 2024 — Nov 2024 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
▶ Show 7 earlier versions
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE3
-
May 2019 — Jan 2021 [monthly]
Completed PHASE3
-
Jun 2018 — May 2019 [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
-
Nov 2017 — Jun 2018 [monthly]
Active Not Recruiting PHASE3
-
Aug 2017 — Nov 2017 [monthly]
Active Not Recruiting PHASE3
-
Feb 2017 — Aug 2017 [monthly]
Active Not Recruiting PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting PHASE3
First recorded
Aug 2009
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Astellas Pharma Canada, Inc.
- Astellas Pharma Inc
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Calgary, Canada , Edmonton, Canada , Halifax, Canada , Hamilton, Canada , London, Canada , Montreal, Canada , Québec, Canada , Saskatoon, Canada , Sherbrooke, Canada , Toronto, Canada and 1 more location